Global Tumor Markers Testing Market set to witness a stable CAGR in the forecast period of 2026
Market Analysis and Insights:- Global Tumor Markers Testing Market
Global Tumor Markers Testing Market By Types (Human Chorionic Gonadotropin (HCG or b-HCG), Cancer Antigen 15-3 (CA15-3), Alpha-Fetoprotein (AFP), Carbohydrate Antigen 19-9 (CA19-9), Cancer Antigen 125 (CA125), Carcinoembryonic Antigen (CEA), Prostate-Specific Antigen (PSA)), Organ (Bladder, Breast, Colorectal, Gastrointestinal, Liver, Lung, Oral, Ovarian, Pancreatic, Prostatic, Skin Testicular Cancer, Leukemia, Lymphoma, Others), End- Users (Hospitals, Commercial/Private Laboratories, Physician Offices/Group Practices, Ambulatory Care Centers), Products (Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains, Others), Methods (Screening, Imaging, Theranostics, Signoidoscopy, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026
Market Analysis: Global Tumor Markers Testing Market
Global tumor markers testing market is set to witness a stable CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. Rising cases of cancer worldwide and rising research on tumor marker is the major factors fueling the growth of this market.
Get More Insights About the Global tumor markers testing market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-tumor-markers-testing-market
Market Definition: Global Tumor Markers Testing Market
Tumor marker is a type of the biomarker which is usually found in the urine, blood and body tissues in patients with some kind of cancers. It is formed by the tumor itself. Tumor marker tests alone are not used to detect cancers because every cancer doesn’t have tumor marker. Carbohydrate Antigen 19-9, Cancer Antigen 15-3, human chorionic gonadotropin, carcinoembryonic antigen, prostate-specific antigen, alpha-fetoprotein, cancer antigen 15-3 are some of the type of the tumor marker. Rising cases of the cancer is the major factor fueling the growth of this market.
Rising aging population is driving the growth of this market
Increasing cases of cancer among population is another factor driving market
Large investments on R&D in the field of cancer detection is driving the growth of this market
Improvement in the government policies is another important factor driving the market growth
High cost of the tumor testing is restraining the market growth
Lack of skilled and trained professionals is another factor restraining the market
Segmentation: Global Tumor Markers Testing Market
Human Chorionic Gonadotropin (HCG or b-HCG)
Cancer Antigen 15-3 (CA15-3)
Carbohydrate Antigen 19-9 (CA19-9)
Cancer Antigen 125 (CA125)
Carcinoembryonic Antigen (CEA)
Prostate-Specific Antigen (PSA)
Skin Testicular Cancer
By End- Users
Physician Offices/Group Practices
Ambulatory Care Centers
Colony Stimulating Factors
Rest of South America
Rest of Europe
Rest of Asia Pacific
United Arab Emirates
Rest of Middle East & Africa
Know more about this https://www.databridgemarketresearch.com/reports/global-tumor-markers-testing-market
Key Developments in the Market:
In July 2018, Exosomics Siena S.p.A. announced the launch of their new liquid biopsy solutions SeleCTEV DNA and SortEV RNA which is specially designed for the selective isolation of tumor-derived nucleic acids with the use of the biofluids like serum or plasma. The main aim is to expand their new liquid biopsy tests and this also help them to expand their analytical kit which can monitor their cancer patients.
In September 2015, Fujirebio Europe announced the launch of their new Lumipulse G Pepsinogen I and Pepsinogen II which will help them to expand their Lumipulse G tumor marker panel. This launch will help the company to strengthen them in the oncology IVD testing. This test can be done CLEIA-based LUMIPULSE G systems, the LUMIPULSE G600II and the LUMIPULSE G1200.
Competitive Analysis: Global Tumor Markers Testing Market
Global tumor markers testing market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of tumor markers testing market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Competitors: Global Tumor Markers Testing Market
Few of the major competitors currently working in the global tumor markers testing market are Abbott, ARCA Biopharma, Danaher, BD, Bio-Rad Laboratories, Inc., Menarini Silicon Biosystems, Inc., Cepheid, deCODE genetics, Diagnocure, DiaSorin, Enzo Biochem Inc., Exact Sciences Corporation, Fujirebio, GUIDED THERAPEUTICS, INC, Hologic, Inc., Leica Biosystems Nussloch GmbH, Oncolab Inc, Ortho-Clinical Diagnostics, Panacea Biotec Ltd., Polymedco.com, F. Hoffmann-La Roche Ltd, SCIENION AG, Siemens, Takara Bio Inc., Thermo Fisher Scientific, Takeda Pharmaceutical Company Limited.
Research Methodology: Global Tumor Markers Testing Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-tumor-markers-testing-market
The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Reasons to Purchase this Report
Current and future of global tumor markers testing market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Access Full report https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-tumor-markers-testing-market
Customization of the Report:
All segmentation provided above in this report is represented at country level
All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Data Bridge Market Research
Hello mama! Look at you, you’ve come so far. Great job! You must be wondering, quad what?
Now that you are in your second trimester, your doctor will advise you to go through some more prenatal screening tests. One out of which is triple or quadruple screening. The screening is done to detect the risk for chromosomal abnormalities that can cause birth defects. In India, approximately 1 out of 166 births are affected by birth defects which makes it a major concern and necessary to get screened for birth defects. Birth defects are conditions present from birth. Some birth defects can happen because of the genes passed by parents and some due to the problem with chromosomes. There is a higher risk of birth defects if you are older than 35 years, have a family history of birth defects, have a medical condition of your own like diabetes or obesity, or due to the use of certain drugs or medicine. So, as for now you probably have understood the importance of triple or quadruple screening. Let’s get into some details.
What is a triple or quadruple screen test?
A triple or quadruple test is also known as multiple marker test, extended AFP, AFP Plus. It is a basic blood test done between 15 and 20 weeks of the gestation period to detect the level of different substances in your blood: estriol, human chorionic gonadotropin (hCG), alpha-fetoprotein (AFP), and, in case of a quad screen, inhibin-A.
Estriol is estrogen that comes both from your placenta and the baby while HCG and inhibin-A are made entirely by the placenta. AFP is a protein made by your baby and passes in a small amount from the placenta to your blood. These together determine the potential to develop any birth defects. The test determines your risk of having a child with Down’s Syndrome, trisomy 18, and neural tube defects (spina bifida and anencephaly)
Wait! I am getting confused. What is the difference between a triple and a quadruple screening?
The only difference between both is that the quad screen is more apt for identifying the risk of Down’s Syndrome and is more accurate than the triple screen test.
How is it done?
Don't you worry! It is a blood test and then the sample is tested for AFP, hCG, estriol, and Inhibin -A levels. The health professional will
Wrap an elastic band around your upper arm making the targeted vein more accessible.
Clean the area of the skin where a needle is to be inserted
Put the needle into the vein
Attach a tube to the needle to fill the vial with blood
Remove the band
Put a cotton ball or gauze pad over the needle site
There is no special instruction or preparation required for the test, so make up your mind and test as soon as you are ready for it.
Okay! So now that the test has been done, how do you interpret the result?
Well, the best person to tell you about the results is your doctor, leave it on him/her. But still, you can analyze the results on your level.
A “positive” result means that there is a higher than average chance your baby has a genetic disorder whereas a “negative” or normal means that your baby probably doesn’t have any genetic disorder.
Low AFP- Indicates risk for neural tube defect
Low AFP, low Estriol, and high HCG level- indicate the possibility for Down’s syndrome
Low level of all markers- Indicates the risk for Edward syndrome.
If your results are positive, your doctor may want you to take a diagnostic test known as amniocentesis or chorionic villus sampling (CVS). The fluid surrounding your baby in the uterus is collected using a small needle and a sample of cells is withdrawn from your placenta in the tests respectively. Then these samples are cultured in the lab and checked to find any chromosomal abnormality. It is totally up to you whether you want to go for further tests or not. You can talk to a genetic counselor or your doctor about what you should do next. We hope you have a healthy munchkin!
To learn more click here.
And the list never ends! You keep on hearing new names from your doctor, which probably bothers you. But don’t be. Help yourself by knowing about it.
Now that you are in the second trimester of your pregnancy, you must be listening to the names of some strange tests that your doctor is recommending you to go through.
So, have you heard of the Quad Marker Test or Quadruple Marker Test?
If not yet, you will be soon listening to it or if you have, you must be wondering, what is it about, how is it conducted, is there any risk related to the test, or what are the results in my favor?
The days are already difficult and nauseating, so don’t get stressed about the test. Just relax and keep your eyes open, we are here to help you with this.
Click Here, To know more about Quad Mar`ker Test.
So, let’s first get some basics about the test.
A quad marker screen is simply a blood test. Yes, It’s easy. You just need to give a little sample of your blood and that’s it, you are done. And the rest is taken care of by your doctor. The test is recommended and conducted in your second trimester, mainly between 15-22 weeks necessarily for women who are more than 35 years or having any historical birth defect or complications in the family.
What difference does it make?
There is a great purpose behind this test. The test tells your doctor about the chances that your baby is carrying any genetic or neural disorder, birth defect, or any other complication or not. Your baby is still not diagnosed for any of the problems, it is just a screening test it does not necessarily mean that your baby is going to be affected by some problem. Many babies have made their way to be normal even after some complications.
The test is important because it can detect conditions like Down’s syndrome, neural tube defect, and other chromosomal abnormalities.
To know more about Down’s Syndrome, Click Here
Wanna know how it’s done?
Just a few ounces of your blood.
Your doctor will simply collect your blood sample from one of your veins, which obviously wouldn’t hurt. Now, your doctor’s work is to screen out the levels of four substances found in your blood. The four substances in which your doctor is interested are alpha-fetoprotein, human chorionic gonadotropin, unconjugated estriol, and inhibin-A. The high or low levels of these substances in your blood indicate different complications and risks that your child can have.
You must be worried about the risks involved in this test, as you are a vigilant mother. You’ll be relieved to know that the quad screen does not pose any risks of miscarriage or any other complications. It is just a basic prenatal screening test. However, the results may cause you anxiety but in the end, it depends on you, how you deal with it.
Worried about the results? Don't be, keep calm!
The healthcare provider analyzes the test results by using your age at the estimated time of delivery and determines your chances of carrying a baby with chromosomal defects, neural tube defects, and abdominal wall defects. Certain factors affect the substances measured by a quad screen like:
Smoking during pregnancy,
Carrying more than one baby,
A miscalculation of how long you’ve been pregnant.
A “positive” result simply means that the levels of some or all the substances in your blood were outside the normal range. In this case, the doctor might recommend an ultrasound to check the baby’s gestational age and find out the number of babies you are carrying. You may also choose to go for further tests like:
Prenatal cell-free DNA screening,
Chorionic villus sampling (CVS),
Remember! The quad screen results only indicate your probability of carrying a baby with birth defects and are not 100% accurate. Consult a genetic counselor or your doctor to understand the test results better.
Want to know more about the Quad Marker Test, Click Here
https://www.acog.org/Patients/FAQs/Prenatal-Genetic-Screening-Tests. Accessed Oct. 11, 2018.
https://www.womenshealth.gov/pregnancy/youre-pregnant-now-what/prenatal-care-and-tests. Accessed Oct. 11, 2018.
Cardiac Marker Testing Market to Progress at a Healthy CAGR in Coming Years
The growing incidence of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public and private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are expected to restrain market growth to a certain extent.
The report Cardiac Marker Testing Market size is estimated to be USD 3.6 billion in 2020 and projected to reach USD 5.5 billion by 2025, at a CAGR of 8.9 %.
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64885447
The cardiac marker testing market includes major Tier I and II suppliers like Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US). These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well.
The cardiac marker testing market is also faced a period of short-term negative growth, which can be attributed to factors such as a greater than 50% drop in the number of patients with cardiovascular conditions and those diagnosed with myocardial infarction. All areas of cardiology service provision sustained significant reductions, which included outpatient clinics, investigations, procedures, and cardiology community services such as cardiac rehabilitation.
Wide use of reagents and kits in all basic diagnostic activities in laboratories, academic institutes, and POC settings is expected to result in the segment occupying the majority of the cardiac marker testing market share
Growing number of cardiac marker testing procedures, accessibility to a wide range of cardiac biomarker reagents and kits, and the growing demand for reliable, specific, and faster
detection of cardiovascular diseases at an early stage are the key growth factors for this segment.
Troponin I and T estimated to be the fastest-growing market
Troponin I and T is estimated to be the fastest-growing segment in the cardiac marker testing market. The large share of this segment can be attributed high sensitivity and specificity, long elevation times, and rapid prediction of outcome or mortality.
North America is estimated to be the largest market due increasing incidence of cardiovascular diseases, growing public and private investments, NIH support for the development of novel cardiac biomarkers, and the rising geriatric population.
Asia Pacific likely to emerge as the largest cardiac marker testing market, globally
Asia Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period. The Asia Pacific market is driven due increased healthcare spending by a larger population base, healthcare infrastructure modernization, and the rising penetration of cutting-edge clinical laboratory technologies (especially in rural areas) in Asia Pacific countries.
Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=64885447
Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US) are the key players in the global cardiac marker testing market.
1 note · View note